Nicholas J. Robert, MD

Real-world evidence is finding an expanded role in oncology, prompting experts to rethink how data are gathered on the day-to-day usefulness of drugs for regulatory decisions.

Nicholas Robert, MD, discusses the importance of evaluating trends in biomarker testing in metastatic non–small cell lung cancer.

Nicholas J. Robert, MD, medical oncology, hematology, Virginia Cancer Specialists, US Oncology, discusses the MA.17R trial, which explored an extension of adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.